{"id":"NCT00086502","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","officialTitle":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2005-11","completion":"2005-11","firstPosted":"2004-07-05","resultsPosted":"2010-04-19","lastUpdate":"2016-02-05"},"enrollment":353,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Comparator: Sitagliptin","otherNames":["Januvia"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]},{"type":"DRUG","name":"Comparator: Pioglitazone","otherNames":["ACTOS"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Sitagliptin 100 mg","deltaMin":-0.85,"sd":null},{"arm":"Placebo","deltaMin":-0.15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17157112"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":175},"commonTop":["Any Infections And Infestations","Upper Respiratory Tract Infection","Any Nervous System Disorders","Headache"]}}